For the Inventor, By the Inventor

Enter assignee name

Obi Pharma Inc.

USPTO Granted Patents = 26

CIPO Patents = 1

EPO Patents = 10

Forward Citations = 18

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Cheng-Der Tony Yu (15 out of 16 patents)

I-Ju Chen (14 out of 16 patents)

Jiann-Shiun Lai (10 out of 10 patents)

4. Cheng-Chi Wang (6 out of 10 patents)

5. Yi-Chien Tsai (5 out of 5 patents)

6. Jian-Xin Duan (5 out of 18 patents)

7. Yeyu Cao (5 out of 7 patents)

8. Xiaohong Cai (5 out of 7 patents)

9. Jing Yuan Ma (5 out of 6 patents)

10. Yih-Huang Hsieh (5 out of 5 patents)

11. Hailong Jiao (5 out of 12 patents)

12. Mark D Matteucci (5 out of 65 patents)

13. Yu-Hsin Lin (3 out of 72 patents)

14. Nan-Hsuan Wang (3 out of 3 patents)

15. Chiu-Chun Lin (3 out of 3 patents)

Core Competencies:

Stable Injection Preparation

CRM197 Protein Expression

Saponin Adjuvant

Carbohydrate Vaccine

Antibodies

Cancer Immunotherapy

Glycoprotein Engineering

Immunogenic Compositions

DNA Alkylating Agents

Glycan Arrays

Pharmaceutical Compositions

High Enantioselectivity

26 patents: Sort by Forward Citations

1. 12629385 - Stable AST-3424 injection preparation and preparation method (2026-05-19),

2. 12234266 - CRM197 protein expression (2025-02-25),

3. 12221461 - Saponin adjuvant and evaluation method thereof (2025-02-11),

4. 12090212 - Conjugated biological molecules, pharmaceutical compositions and methods (2024-09-17),

5. 12053514 - Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment (2024-08-06),

6. 11833223 - Antibodies, pharmaceutical compositions and methods (2023-12-05),

7. 11773118 - Methods of making high enantioselective secondary alcohols (2023-10-03),

8. 11752204 - Vaccines with higher carbohydrate antigen density and novel saponin adjuvant (2023-09-12),

9. 11643456 - Human antibodies, pharmaceutical compositions and methods (2023-05-09),

10. 11642400 - Immunogenic/therapeutic glycan compositions and uses thereof (2023-05-09),

11. 11583577 - Cancer immunotherapy by immune activation or immune modulation via Globo series antigens (2023-02-21),

12. 11535585 - Nitrobenzyl derivatives of anti-cancer agents (2022-12-27),

13. 11236154 - Carbohydrate antibodies, pharmaceutical compositions and uses thereof (2022-02-01),

14. 11203645 - Glycosynthase variants for glycoprotein engineering and methods of use (2021-12-21),

15. 11041017 - Antibodies, pharmaceutical compositions and methods (2021-06-22),

Obi Pharma Inc. is a biotechnology company based in Taipei, Taiwan, specializing in the development of innovative therapies for cancer treatment. The company focuses on advancing its proprietary drug candidates through rigorous research and clinical trials, targeting various cancer types with a commitment to improving patient outcomes. Obi Pharma leverages cutting-edge technology and scientific expertise to explore novel therapeutic approaches, positioning itself as a key player in the global biopharmaceutical landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

26 Patents

#142 in Taipei

#661 in Taiwan

#24,758 in the World

Obi Pharma Inc.

Forward Citations = 18

46 inventors:

Cheng-Der Tony Yu (15 out of 16 patents)

I-Ju Chen (14 out of 16 patents)

Jiann-Shiun Lai (10 out of 10 patents)

4. Cheng-Chi Wang (6 out of 10 patents)

5. Yi-Chien Tsai (5 out of 5 patents)

Please report any incorrect information to [email protected]

Loading…